AstraZeneca Korea announced on the 5th that it has obtained permission from the Ministry of Food and Drug Safety for the Forxiga combination 'Sidapvia (Dapagliflozin 10mg + Sitagliptin 100mg)'. Sidapvia, approved as a treatment for type 2 diabetes, is a combination drug that combines the SGLT-2 inhibitor Dapagliflozin's original product Forxiga and the DPP-4 inhibitor Sitagliptin (Januvia). In 2020, AstraZeneca entered into an agreement with SK Chemicals to develop and produce Forxiga combinations and started developing combinations. SK Chemicals will be in charge of production and supply of Sidapvia, and AstraZeneca will be in charge of commercialization strategy and execution. According to the guidelines of the Kor